DTCFF (Defence Therapeutics) PB Ratio: 6.64 (As of Jun. 27, 2026)


DTCFF Defence Therapeutics Inc DTCFF
21 GF Score
Price $0.35
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics PB Ratio?

Defence Therapeutics DTCFF -2.02% 21 PB Ratio is 6.64 as of Jun. 27, 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, Defence Therapeutics ranks worse than 79.3% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Defence Therapeutics's share price is $0.3451. Defence Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.05. Hence, Defence Therapeutics's PB Ratio of today is 6.64.

The historical rank and industry rank for Defence Therapeutics's PB Ratio or its related term are showing as below:

DTCFF' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 13.25
Current: 8.63

During the past 6 years, Defence Therapeutics's highest PB Ratio was 13.25. The lowest was 0.00. And the median was 0.00.

DTCFF's PB Ratio is ranked worse than
79.3% of 1232 companies
in the Biotechnology industry
Industry Median: 2.8 vs DTCFF: 8.63

During the past 3 years, the average Book Value Per Share Growth Rate was -27.90% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Defence Therapeutics was -12.60% per year. The lowest was -27.90% per year. And the median was -20.25% per year.

Back to Basics: PB Ratio


Defence Therapeutics  (OTCPK:DTCFF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Defence Therapeutics PB Ratio Related Terms


Defence Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics PB Ratio Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PB Ratio
Get a 7-Day Free Trial 49.53 0.00 79.11 0.00 0.00

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 7.69

DTCFF vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Defence Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's PB Ratio falls into.


DTCFF
21GF Score
Defence Therapeutics Inc DTCFF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Defence Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.3451/0.052
=6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 6.64 mean?
Defence Therapeutics (DTCFF) has a PB Ratio of 6.64 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Defence Therapeutics and its competitors. According to the industry distribution chart, Defence Therapeutics ranks #977 out of 1232 companies in the Biotechnology industry, placing it in the top 79.3%.
Is Defence Therapeutics' PB Ratio too high?
Defence Therapeutics' current PB Ratio is 6.64. The Biotechnology industry median PB Ratio is 2.80. Defence Therapeutics' value of 6.64 is 137.1% above this industry median. Based on the distribution chart, Defence Therapeutics ranks #977 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Defence Therapeutics ranks #977 out of 1232 companies for PB Ratio. This places Defence Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Defence Therapeutics' value of 6.64 is 137.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Defence Therapeutics's current PB Ratio of 6.64 is 137.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Defence Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Defence Therapeutics's current PB Ratio is 6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current PB Ratio of 6.64. The current PB Ratio is 6.64 and 137.1% above the Biotechnology industry median of 2.80. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current PB Ratio is 6.64 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score

Get the complete analysis for DTCFF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price